New study shows that ranibizumab used in a treat-and-extend regimen cuts clinic visits by 46% for patients with Diabetic Macular Oedema

Data from a new study shows that ranibizumab (Lucentis®) used in a treat-and-extend (T&E) regimen cuts clinic visits by 46% for patients with Diabetic Macular Oedema (DMO) - one of the leading...

Full Story →